PARI’s Pipeline is focused primarily on projects
in select markets where there appears to be
little or no real interest from pharmaceutical
companies. As the first phase for these
projects, PARI will work on commercialization in
Europe. The data and IP generated in these
European development projects present a
potential pharmaceutical partnering or licensing
opportunity in North America.
Currently we are utilizing our Advanced Aerosol
Delivery platform—eFlow—unless otherwise
specified in the graph below. We are preparing
for future development with the PARI Sinus ™
platform that will concentrate on chronic
sinusitis. New therapy development with the PARI
Sinus will begin with specific patient groups,
such as pre-sinus surgery patients.
[enlarge
view]
|
